Trial Profile
Phase II Combination of Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Lirilumab (Primary) ; Nivolumab (Primary) ; Azacitidine
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 17 Dec 2019 Status changed from completed to discontinued.
- 31 Jan 2019 Status changed from active, no longer recruiting to completed.
- 23 Feb 2018 Status changed from recruiting to active, no longer recruiting.